How effective is Omalizumab treatment? Summary of efficacy data

Omalizumab is an anti-IgE targeted biological agent that has shown significant efficacy in the treatment of moderate to severe allergic asthma and chronic spontaneous urticaria. In the field of asthma, multiple large-scale clinical trials have shown that omalizumab can effectively reduce the number of acute asthma exacerbations, improve lung function, and improve patients' quality of life. For example, one study (the INNOVATE study) showed that adding omalizumab to conventional treatment can reduce the annual rate of severe asthma attacks by up to 55% and patients’ nighttime symptoms are significantly reduced.

For patients with chronic spontaneous urticaria, the efficacy of omalizumab is equally impressive. According to ASTERIA I and II and other multi-center clinical study data, inject omalizumab 300mg every 4

The efficacy of long-term use of omalizumab has also been continuously verified. A follow-up study lasting more than one year found that asthma patients who maintained omalizumab not only experienced a significant reduction in the number of exacerbations, sustained improvements in lung function, and also reduced their dependence on oral corticosteroids. In the treatment of urticaria, some patients can achieve stable disease after continuous medication for 6 months, and then try to reduce the dose or even discontinue the medication, but still maintain a long remission period, indicating that it may have a "disease-modifying" effect.

Overall, the therapeutic effect of omalizumab has clear evidence support in multiple indications, with a relatively quick onset of action and good tolerability. It has demonstrated broad clinical adaptability and high patient satisfaction, both in patients with allergic asthma and chronic urticaria. In the future, its indications may be further expanded to include nasal polyps, food allergies and other diseases, bringing new treatment hope to more patients.

Reference materials:https://www.drugs.com/